AXT, Inc. (AXTI) | The Buildout — AI Infrastructure
The Verdict
AXT, Inc. manufactures compound semiconductor substrates — the crystalline wafers that other companies grow lasers, detectors, and photonic devices on. Its indium phosphide wafers are the base layer for the high-speed optical lasers and transceivers that carry data inside AI data centers. The company sells no systems, modules, or compute; it sells the substrate underneath them, one step upstream of the laser and transceiver makers that sell directly into the build-out. Because that substrate is a recognized chokepoint, AXT's position depends both on its ability to grow and qualify wafers at volume and on Chinese export permits that govern where it can ship them.
| Market Cap | — |
| Revenue (TTM) | $126M |
| Revenue Growth | +45.8% |
| EBITDA Margin (TTM) | 10.7% |
| Net Cash | $332M |
| Earnings Beats | 3 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- InP revenue reached a record $30.7M in Q2 2026, up about 126% sequentially, and is roughly two-thirds of consolidated revenue on an analyst estimate.
- Three long-term supply agreements were announced or signed within roughly three months — Coherent ($25.4M prepayment), Casella ($22.3M prepayment), and Lumentum — a customer-funded form of demand evidence.
- InP backlog is 'well over $100 million' and extends into 2027, and management says the figure understates demand because it is not booking orders beyond planned capacity.
- Cash and short-term investments of $417.2M against $85.4M of total debt — a net cash position of $331.8M — after a ~$632.5M gross secondary offering closed April 22, 2026.
- Management raised InP capacity targets twice in two quarters: exiting-2026 from ~$35M/q to ~$60M/q, and exiting-2027 from $65–70M/q to ~$130M/q.
What We’re Watching
- Export-permit timing is the binding near-term constraint: the Q3 guide covers revenue already permitted or not requiring a permit, and management says it cannot predict permit timing or success.
- Customers are also becoming suppliers — Coherent is doubling internal InP output year over year and more than doubling again by end-2027; Broadcom says it is more than tripling its InP factories year-on-year.
- Inventory has risen two quarters running, to $96.3M at 6/30/26, against a stated plan to bring it down.
- U.S. permits remain ungranted; North America was $207K, or 1% of Q1 2026 revenue, down 81.3% year over year.
On the evidence in the record, the thesis is strengthening on demand and margin: a demand-to-supply flip, a first profitable quarter that beat the guide, record InP revenue, and customer prepayments booked as liabilities. What is not established is durability. The 45% gross margin rests on full utilization of the whole diameter range and a mix shift toward InP, and the customers paying that scarcity premium are the same companies adding internal InP lines. The open question is whether the permit-gated supply gap and current margin hold long enough for the 2027 capacity build to convert into revenue.
Earnings
AXT reported Q2 2026 revenue of $47.6M, the highest quarter in company history, up 77% sequentially from $26.9M and 164% from $18M a year earlier. Non-GAAP gross margin was 45.0%, against 29.9% in Q1 2026 and 8.2% in Q2 2025. Indium phosphide revenue set a record at $30.7M, up from $13.6M the prior quarter, and GAAP net income was $11.1M, or $0.17 per diluted share — the company's first profitable quarter in two years.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $48M | $27M | $18M | +164.4% |
| Gross margin | 44.9% | 29.6% | 8.0% | +3690bps |
| EBITDA | $13M | $1M | −$4M | −386.7% |
| EPS | $0.17 | $-0.03 | $-0.16 | −209.1% |
| Indium phosphide revenue | $30.7M | $13.6M | n/a | — |
The demand is moving faster than we can move. We are doing great to move fast.— Gary L. Fischer, CFO, 2026-07-30
Management tone: Management's tone escalated between the two calls in the record. The Q1 2026 call was framed around a permit-secured revenue floor and a conservative margin reference of 35%; on the Q2 2026 call management used words like 'inflection' and 'step function,' named a gross-margin target 'that begins with a 5,' and said demand was moving faster than the company could move. In questions, management answered capacity numbers directly, confirmed the exit-2026 per-quarter capacity figure, and declined to give an exact backlog number, saying it is not booking orders beyond planned capacity.
Management Guidance
For Q3 2026, management guided to approximately $66M of revenue that is already permitted or does not require an export permit, with 'significant upside' possible if additional permits arrive — while stating it cannot predict permit timing. It guided non-GAAP net income of $0.30–$0.32 and GAAP net income of $0.29–$0.31, non-GAAP OpEx of ~$10.5M and GAAP OpEx of ~$11M, and a share count of ~66.5M. On gross margin, management recommended modeling close to current levels near-term while naming a longer-term target 'that begins with a 5.'
Trajectory
Revenue stepped rather than sloped: $28M in Q3 2025, $23M in Q4 2025, $26.9M in Q1 2026, then $47.6M in Q2 2026, a 77% sequential jump. Gross margin moved the same way — 44.9% in Q2 2026 against 29.6% in Q1 2026 and negative 6.4% in Q1 2025. Management attributes the improvement to volume and mix: fixed factory costs spread over more units, plus a shift toward higher-margin indium phosphide. InP supplied roughly $17.1M of the $20.7M sequential revenue increase, so the step is an InP event rather than broad-based growth. Free cash flow was –$13.1M in Q1 2026 and $3.6M in Q2 2026, so cash generation has not yet matched the earnings swing.
The Model
The model projects FY+1 revenue of $221.5M with EBITDA of $65M (29.2% margin), and FY+2 revenue of $455.0M with EBITDA of $185M (40.55% margin). FY+1 sits between management's exiting-2026 InP capacity target of ~$60M per quarter and the ~$130M per quarter target for exiting 2027, and depends on the 2026 capacity build finishing and on export permits converting into shipments. FY+2 assumes the 2027 adjacent-facility build lands and InP volumes scale toward that target.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $88M | $222M | $455M |
| YoY Growth | — | +150.6% | +105.4% |
| EBITDA | −$13M | $65M | $185M |
| EBITDA Margin | -14.6% | 29.2% | 40.5% |
Projections are the median of 4 independent model runs. The model’s revenue sits 124.8% above analyst consensus.
For Q3 2026, management guided to approximately $66M of revenue that is already permitted or does not require an export permit, with 'significant upside' possible if additional permits arrive — while stating it cannot predict permit timing. It guided non-GAAP net income of $0.30–$0.32 and GAAP net income of $0.29–$0.31, non-GAAP OpEx of ~$10.5M and GAAP OpEx of ~$11M, and a share count of ~66.5M. On gross margin, management recommended modeling close to current levels near-term while naming a longer-term target 'that begins with a 5.'
What Could Go Right — and Wrong
- U.S. export permits are granted, opening a geography that was $207K, or 1% of revenue, in Q1 2026 and adding the flagged Q3 upside.
- The 2026 InP capacity build finishes on schedule and the 2027 adjacent facility comes online toward the ~$130M per quarter exit target.
- 6-inch InP moves from customer qualification into volume production, lifting revenue and margin per wafer.
- A fourth or fifth prepayment-funded long-term supply agreement lands, hardening forward revenue.
- Gross margin holds at or above 45% as revenue scales, keeping the operating-leverage story intact.
- Export permits stall, and revenue reverts toward the permit-free base rather than the Q3 guide.
- Customer and competitor InP capacity arrives ahead of demand, easing the scarcity that is producing current pricing and margin.
- Gross margin rolls back toward the 30s, breaking the operating-leverage assumption behind the Q3 guide.
- A long-term supply agreement customer qualifies a second substrate source at scale, or a contract slips — Casella's does not start until 2027.
- Capacity execution slips: the 2026 build is brownfield, the 2027 build depends on an adjacent acquired building, and the 2028 greenfield plan is not yet sited.
Looking Ahead
Over the next twelve months the story is capacity and permits. Management points to doubling InP capacity in 2026 and more than tripling the InP revenue opportunity by year-end, then roughly doubling again in 2027. The 2028 greenfield plan, with CapEx of ~$220–250M, is in planning. The customer contracts set to contribute are the Coherent and Casella agreements (with Casella not starting until 2027), the Lumentum agreement, and 6-inch qualifications. Co-packaged and near-packaged optics are flagged as a second inflection 'beginning in late 2027 and beyond.'
- Q3 2026Q3 results vs. guide — Tests the permit-secured Q3 revenue floor and a 45% margin.
- Q3 2026Export permit decisions — Upside to the Q3 guide depends on additional permits arriving.
- End of 2026InP capacity doubling — Revenue opportunity to more than triple by year-end.
- 2027Casella contract start — Prepayment converts to revenue as shipments begin.
- Exiting 2027Second InP doubling — Target from the adjacent facility; roughly double the prior exit rate.
- Late 2027 and beyondCPO/NPO inflection — Co-packaged optics flagged by management as a second demand inflection.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $99M | $88M | $126M | -11.0% |
| Gross Margin | 24.0% | 11.2% | 32.2% | 1,278bps |
| EBITDA | −$6M | −$13M | $13M | -122.4% |
| EBITDA Margin | -5.8% | -14.6% | 10.7% | 875bps |
| Net Income | −$12M | −$21M | $4M | -82.8% |
| Free Cash Flow | −$18M | −$19M | −$20M | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)32.2%
- EBITDA Margin (TTM)10.7%
- Net Margin (TTM)3.3%
- ROIC0.6%
- FCF Conversion-145.5%
- SBC / Revenue3.0%
The Company
AXT develops and produces high-performance compound and single element semiconductor substrates — wafers — and sells raw materials used to make them. Its substrate products are indium phosphide (InP), gallium arsenide (GaAs) and germanium; its raw materials include 6N+ and 7N+ purified gallium, boron trioxide, gallium-magnesium alloy, and pyrolytic boron nitride crucibles. The 10-K describes InP as 'a high-performance semiconductor wafer substrate used in broadband and fiber optic applications, 5G infrastructure and data center connectivity.' InP is now the dominant growth and margin driver: management ties it primarily to data center applications.
The company reports two product lines — specialty material substrates and the raw materials integral to them. In 2025 the Substrate Group was 67% of consolidated revenue and the Raw Materials Group 33%. It owns six production sites, all in China: Beijing, DingXing, two in Kazuo run by AXT/Tongmei, a Kazuo and Tianjin site run by Beijing BoYu, and a Kazuo site run by ChaoYang JinMei Gallium. Long-lived assets, net, were $165.5M in China versus $0.97M in North America at 3/31/26. It is vertically integrated into its own inputs — JinMei refines high-purity indium and BoYu makes pBN crucibles and high-purity materials — which management calls a competitive differentiator.
Business Segments
Competitive Landscape
The 10-K names six competitors: Sumitomo Electric Industries, Japan Energy ('JX'), Freiberger Compound Materials, Umicore, China Crystal Technology Corp. ('CCTC') and Vital Materials. Management's own framing on the Q2 2026 call is that 'the competitive landscape for high quality indium phosphide is limited to just a few players. Due to primarily the very high technical barrier to entry,' and that AXT believes it is in the strongest position to add capacity quickly. The 10-K's risk language cuts the other way: competitors selling substrates made with similar crystal-growth technology 'has eroded our technological differentiation,' and trade tensions could produce new domestic Chinese competitors.
- A customer under a long-term supply agreement and a competitor with captive InP production; its own call said 'Indium Phosphide capacity continues to be our primary constraint.'
- Sumitomo Electric IndustriesNamed in filings; not discussed.
- Japan Energy ('JX')Named in filings; not discussed.
- Freiberger Compound MaterialsNamed in filings; not discussed.
- China Crystal Technology Corp. ('CCTC')Named in filings; not discussed.
Supply Chain
AXT sits one step upstream of the AI optics chain: it supplies indium phosphide wafers to the laser and transceiver makers that sell into hyperscalers. Lumentum's CEO named the company directly on Lumentum's own earnings call.
More on AXTI: Earnings recap